Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Current Deferred Revenue (2019 - 2022)

Historic Current Deferred Revenue for Lyell Immunopharma (LYEL) over the last 4 years, with Q3 2022 value amounting to $11.2 million.

  • Lyell Immunopharma's Current Deferred Revenue rose 10051.96% to $11.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $11.2 million, marking a year-over-year increase of 10051.96%. This contributed to the annual value of $5.0 million for FY2021, which is 1816.24% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Current Deferred Revenue of $11.2 million as of Q3 2022, which was up 10051.96% from $15.4 million recorded in Q2 2022.
  • In the past 5 years, Lyell Immunopharma's Current Deferred Revenue ranged from a high of $45.0 million in Q4 2019 and a low of $5.0 million during Q4 2021
  • Its 4-year average for Current Deferred Revenue is $12.8 million, with a median of $7.2 million in 2021.
  • In the last 5 years, Lyell Immunopharma's Current Deferred Revenue crashed by 8645.56% in 2020 and then surged by 10051.96% in 2022.
  • Quarter analysis of 4 years shows Lyell Immunopharma's Current Deferred Revenue stood at $45.0 million in 2019, then plummeted by 86.46% to $6.1 million in 2020, then decreased by 18.16% to $5.0 million in 2021, then soared by 124.36% to $11.2 million in 2022.
  • Its Current Deferred Revenue stands at $11.2 million for Q3 2022, versus $15.4 million for Q2 2022 and $6.2 million for Q1 2022.